Literature DB >> 21934544

Differential diagnostic value of single-photon emission computed tomography/spiral computed tomography with Tc-99m-methylene diphosphonate in patients with spinal lesions.

Yiqiu Zhang1, Hongcheng Shi, Yushen Gu, Yan Xiu, Beilei Li, Weimin Zhu, Shuguang Chen, Haojun Yu.   

Abstract

PURPOSE: The objective of this study was to compare the diagnostic value obtained using single-photon emission computed tomography (SPECT)/spiral computed tomography (CT) with Tc-99m methylene-diphosphonate with that obtained using SPECT alone in patients with spinal lesions.
METHODS: This was a retrospective study of 56 patients who underwent planar whole-body scintigraphy because of bone pain or osseous lesions that had been detected by other imaging techniques, or for the investigation of bone metastasis in patients with extraskeletal malignancies. Only patients who had hot spots detected in their spine and who had undergone single-photon emission computed tomography/computed tomography (SPECT/CT) imaging were included. One lesion from each patient was resected or biopsied for pathological diagnosis, and lesions for which a pathological diagnosis could be made were included in this study. Single-photon emission computed tomography (SPECT) and SPECT/CT images were independently interpreted by two experienced nuclear medicine physicians who had not been involved in the selection of data for the study. The physicians were aware of patients' sex, age, history of histologically confirmed extraskeletal malignancy, and whole-body scintigraphy results, but were unaware of the results of other investigations, such as X-ray, MRI, and laboratory tests. SPECT images were analyzed first, followed by SPECT/CT images. Each lesion was graded on a 4-point diagnostic scale (1, benign; 2, likely benign; 3, likely malignant; 4, malignant), and the inter-reviewer agreement and the agreement of the SPECT and SPECT/CT diagnoses with the pathology results were evaluated by κ scores.
RESULTS: The pathology results revealed 39 malignant bone tumors and 17 benign lesions. In the malignant cases, 20 were bone metastases and 19 were malignant tumors of another histological type. The reviewers rated 67.9% of lesions as equivocal (grade 2-3) by SPECT, but only 19.6% as equivocal by SPECT/CT. The κ scores for inter-reviewer agreement were 0.467 for SPECT and 0.905 for SPECT/CT (both P<0.0001). The κ scores for the agreement of the interpretation of SPECT and SPECT/CT with the pathology results were 0.493 and 0.689, respectively (both P<0.0001).
CONCLUSION: Compared with SPECT imaging, SPECT/spiral CT hybrid imaging significantly reduced the number of lesions judged to be equivocal. This reduction allowed for a definitive diagnosis to be made by imaging in the majority of patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21934544     DOI: 10.1097/MNM.0b013e32834bd82e

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  11 in total

1.  Clinical study of the application of SPECT, CT, and SPECT/CT for diagnosing rib diseases.

Authors:  Runqing Duan; Hongcheng Shi
Journal:  Jpn J Radiol       Date:  2015-01-29       Impact factor: 2.374

2.  A Case Report of a Gluteus Hematoma Detected on 99mTc-MDP Bone Scan.

Authors:  Miju Cheon; Jang Yoo
Journal:  Diagnostics (Basel)       Date:  2022-06-03

3.  Accuracy of whole-body HDP SPECT/CT, FDG PET/CT, and their combination for detecting bone metastases in breast cancer: an intra-personal comparison.

Authors:  Olivier Rager; Stephanie A Lee-Felker; Claire Tabouret-Viaud; Ely R Felker; Antoine Poncet; Gaël Amzalag; Valentina Garibotto; Habib Zaidi; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-06-05

4.  Comparison of SPECT/CT and MRI in diagnosing symptomatic lesions in ankle and foot pain patients: diagnostic performance and relation to lesion type.

Authors:  Seunggyun Ha; Sung Hwan Hong; Jin Chul Paeng; Dong Yeon Lee; Gi Jeong Cheon; Amitabh Arya; June-Key Chung; Dong Soo Lee; Keon Wook Kang
Journal:  PLoS One       Date:  2015-02-10       Impact factor: 3.240

5.  Whole-Body SPECT/CT versus Planar Bone Scan with Targeted SPECT/CT for Metastatic Workup.

Authors:  Olivier Rager; René Nkoulou; Nadia Exquis; Valentina Garibotto; Claire Tabouret-Viaud; Habib Zaidi; Gaël Amzalag; Stephanie Anne Lee-Felker; Thomas Zilli; Osman Ratib
Journal:  Biomed Res Int       Date:  2017-07-24       Impact factor: 3.411

6.  A new SPECT/CT reconstruction algorithm: reliability and accuracy in clinical routine for non-oncologic bone diseases.

Authors:  Olivier Delcroix; Philippe Robin; Maelenn Gouillou; Alexandra Le Duc-Pennec; Zarrin Alavi; Pierre-Yves Le Roux; Ronan Abgral; Pierre-Yves Salaun; David Bourhis; Solène Querellou
Journal:  EJNMMI Res       Date:  2018-02-12       Impact factor: 3.138

7.  3D SPECT/CT fusion using image data projection of bone SPECT onto 3D volume-rendered CT images: feasibility and clinical impact in the diagnosis of bone metastasis.

Authors:  Yuji Ogata; Tadaki Nakahara; Kenichi Ode; Yohji Matsusaka; Mari Katagiri; Yu Iwabuchi; Kazunari Itoh; Akira Ichimura; Masahiro Jinzaki
Journal:  Ann Nucl Med       Date:  2017-02-27       Impact factor: 2.668

8.  Clinical study of 99mTc-3P-RGD2 peptide imaging in osteolytic bone metastasis.

Authors:  Guoqiang Shao; Wei Gu; Muhong Guo; Shiming Zang; Jinjing Fu; Shuang Liu; Feng Wang; Zizheng Wang
Journal:  Oncotarget       Date:  2017-04-27

Review 9.  Target Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular Imaging.

Authors:  Gaël Amzalag; Olivier Rager; Claire Tabouret-Viaud; Michael Wissmeyer; Electra Sfakianaki; Thomas de Perrot; Osman Ratib; Raymond Miralbell; Giampiero Giovacchini; Valentina Garibotto; Thomas Zilli
Journal:  Front Oncol       Date:  2016-03-31       Impact factor: 6.244

10.  Advantages of systematic trunk SPECT/CT to planar bone scan (PBS) in more than 300 patients with breast or prostate cancer.

Authors:  Vincent Fleury; Ludovic Ferrer; Mathilde Colombié; Daniéla Rusu; Maëlle Le Thiec; Françoise Kraeber-Bodéré; Loïc Campion; Caroline Rousseau
Journal:  Oncotarget       Date:  2018-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.